Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
复制标题
血清白细胞介素 6 水平的快速变化可以预测静脉注射的反应性。
DOI：
10.1111/1346-8138.14580
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Sato S.
中科院分区：
文献类型：
--
作者：
Numajiri H;Yoshizaki A;Fukasawa T;Ebata S;Nakamura K;Yamashita T;Saigusa R;Miura S;Hirabayashi M;Yoshizaki A;Sumida H;Asano Y;Kazoe Y;Mawatari K;Kitamori T;Sato S.
系统性硬化症（SSc）是一种以细胞外基质过度沉积为特征的自身免疫性疾病。尽管SSc相关间质性肺病（ILD）是SSc死亡的最重要并发症之一，但SSc-ILD治疗反应性的预测因素仍不清楚。为了评估白细胞介素（IL）-6与治疗反应性之间的关系，我们使用高灵敏度酶联免疫分析系统测量了23例接受环磷酰胺静脉注射（IVCY）治疗的活动性SSc-ILD患者和20例稳定性SSc-ILD患者的血清IL-6水平。活动性SSc‐ILD患者的血清IL‐6水平显著高于稳定性SSc‐ILD患者。在活动性SSc‐ILD患者中，IVCY应答者和非应答者之间的基线血清IL‐6水平无显著差异。同时，在总共六次IVCY剂量中的三次IVCY剂量后，应答者的血清IL-6水平下降，但无应答者则没有。关于三个剂量共六个IVCY的参数变化，血清IL-6水平的变化与肺功能检查值呈负相关。因此，在几次给药期间血清IL-6水平的快速下降可能预测IVCY治疗对SSc-ILD的疗效。
Systemic sclerosis (SSc) is an autoimmune disorder characterized by excessive extracellular matrix deposition. Although SSc‐associated interstitial lung disease (ILD) is one of the most important complications as a cause of death in SSc, prediction factors of treatment reactivity in SSc‐ILD are still unclear. To assess relationships between interleukin (IL)‐6 and reactivity to treatment, we measured serum IL‐6 levels in 23 of active SSc‐ILD patients under i.v. cyclophosphamide (IVCY) therapy and 20 of stabilized SSc‐ILD, using the high‐sensitivity enzyme‐linked immunoassay system. Serum IL‐6 levels in active SSc‐ILD patients were significantly higher than those in stabilized SSc‐ILD patients. Among active SSc‐ILD patients, baseline serum IL‐6 levels were not significantly different between IVCY responders and non‐responders. Meanwhile, serum IL‐6 levels after three IVCY doses out of a total of six were decreased in responders but not in non‐responders. Regarding changes of parameters by the three doses of a total of six of IVCY, change in serum IL‐6 levels correlated inversely with that in values of pulmonary function test. Thus, the rapid decrease in serum IL‐6 levels during a couple of doses may predict the efficacy of IVCY therapy against SSc‐ILD.